Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industriesBusiness Overview: a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe. b) It offers...
Sai Life Sciences reported a strong Q1FY27: Revenue ₹554 Cr (+12% YoY), PAT ₹73 Cr (+22% YoY). CRO business grew 24%. A new 100,000 sq. ft. R&D facility operationalized. Strategic pharma engagements and strong CMC pipeline drive multi-year growth outlook.
Sai Life Sciences (SAILIFE) FY26: Revenue +29% to ₹2,192 Cr, EBITDA +56% to ₹661 Cr, Net Profit +109% to ₹355 Cr. Strong execution and deepening pharma ties drove growth, with significant investments in CRDMO capabilities.
Sai Life Sciences' Bidar campus now runs on 100% renewable power, making it the first Indian CRDMO with a fully green-powered site. This significant operational shift avoids an estimated 35,110 metric tonnes of CO₂ emissions annually.
Sai Life Sciences reported strong Q3FY26: Revenue +27% to ₹556 Cr, EBITDA +54% to ₹191 Cr, PAT +86% to ₹100 Cr. Nine-month results also robust. Company invested ₹405 Cr in capex, advancing AI and technology for future CRDMO growth.
Sai Life Sciences announced a strategic collaboration with Mabtech, establishing its Boston lab as a US hub for the EYRA platform. This enhances Sai's capabilities in advanced immunology assay services, strengthening its offerings for biopharma clients in immune profiling.
